Funding supports Sorrento's staph infection work

Sorrento Therapeutics a two-year, $600,000 grant from the National Institute of Allergy and Infectious Diseases to support the company's develoment of antibody therapeutics and vaccines for Staph infections. The grant will help fund Phase I studies and could eventually lead to funding for Phase II trials. Article

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan